Clinical Trial Update: A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of tapentadol extended-release for painful diabetic peripheral neuropathy has completed and posted results in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• Tapentadol extended-release (Nucynta ER) (Tapentadol)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Diabetic Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2010-01-13